Clinical data
ATC code None
CAS Number 433695-36-4 YesY
PubChem (CID) 2921148
ChemSpider 2194720 N
Chemical and physical data
Formula C9H12N2O4S
Molar mass 244.267 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 subtype.[1] It has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.[2]


  1. Smith, SJ; Cieslinski, LB; Newton, R; Donnelly, LE; Fenwick, PS; Nicholson, AG; Barnes, PJ; Barnette, MS; Giembycz, MA (December 2004). "Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a Selective Inhibitor of Phosphodiesterase 7: in vitro Studies in Human Monocytes, Lung Macrophages, and CD8+ T-Lymphocytes" (PDF). Molecular Pharmacology. 66 (6): 1679–89. doi:10.1124/mol.104.002246. PMID 15371556. Retrieved 5 October 2016.
  2. Pekkinen, M; Ahlström, ME; Riehle, U; Huttunen, MM; Lamberg-Allardt, CJ (July 2008). "Effects of Phosphodiesterase 7 Inhibition by RNA Interference on the Gene Expression and Differentiation of Human Mesenchymal Stem Cell-Derived Osteoblasts". Bone. 43 (1): 84–91. doi:10.1016/j.bone.2008.02.021. PMID 18420479.
This article is issued from Wikipedia - version of the 10/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.